PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35352593-1 2022 PURPOSE: To investigate the effect of tolcapone on cerebrospinal fluid (CSF) transthyretin (TTR) tetramer stability in patients with hereditary transthyretin (ATTRv) amyloidosis. Tolcapone 38-47 transthyretin Homo sapiens 77-90 35352593-1 2022 PURPOSE: To investigate the effect of tolcapone on cerebrospinal fluid (CSF) transthyretin (TTR) tetramer stability in patients with hereditary transthyretin (ATTRv) amyloidosis. Tolcapone 38-47 transthyretin Homo sapiens 92-95 35352593-1 2022 PURPOSE: To investigate the effect of tolcapone on cerebrospinal fluid (CSF) transthyretin (TTR) tetramer stability in patients with hereditary transthyretin (ATTRv) amyloidosis. Tolcapone 38-47 transthyretin Homo sapiens 144-157 35352593-9 2022 Orally administered tolcapone significantly increased CSF TTR concentration and decreased monomer content under semi-denaturing conditions. Tolcapone 20-29 transthyretin Homo sapiens 58-61 32324953-5 2021 Recently, we have repurposed tolcapone as a molecule to treat systemic ATTR. Tolcapone 29-38 transthyretin Homo sapiens 71-75 32324953-6 2021 Crystal structures and biophysical analysis converge to demonstrate that tolcapone binds with high affinity and specificity to three unstable leptomeningeal TTR variants, stabilizing them and, consequently inhibiting their aggregation. Tolcapone 73-82 transthyretin Homo sapiens 157-160 32791384-0 2020 Interactions of tolcapone analogues as stabilizers of the amyloidogenic protein transthyretin. Tolcapone 16-25 transthyretin Homo sapiens 80-93 32791384-2 2020 TTR stabilizers, such as tolcapone, an FDA approved drug for Parkinson"s disease, are able to interact with residues of the thyroxine-binding sites of TTR, both wild type and pathogenic mutant forms, thereby stabilizing its tetrameric native state and inhibiting amyloidogenesis. Tolcapone 25-34 transthyretin Homo sapiens 0-3 32791384-2 2020 TTR stabilizers, such as tolcapone, an FDA approved drug for Parkinson"s disease, are able to interact with residues of the thyroxine-binding sites of TTR, both wild type and pathogenic mutant forms, thereby stabilizing its tetrameric native state and inhibiting amyloidogenesis. Tolcapone 25-34 transthyretin Homo sapiens 151-154 32791384-5 2020 In the two TTR-ligand complexes the tolcapone analogues establish mainly H-bond and hydrophobic interactions with residues of the thyroxine-binding site of the TTR tetramer. Tolcapone 36-45 transthyretin Homo sapiens 11-14 32791384-5 2020 In the two TTR-ligand complexes the tolcapone analogues establish mainly H-bond and hydrophobic interactions with residues of the thyroxine-binding site of the TTR tetramer. Tolcapone 36-45 transthyretin Homo sapiens 160-163 32791384-8 2020 Our data, coupled with previously reported data on the pharmacokinetics properties in humans of tolcapone and 3-O-methyltolcapone, further support the relevance of the latter tolcapone analogue as TTR stabilizer. Tolcapone 120-129 transthyretin Homo sapiens 197-200 32708961-3 2020 In recent years, it has been shown that tolcapone is a potent inhibitor of the amyloid aggregation process of the transthyretin protein, and acts by stabilizing the structure of the protein, reducing the progression of familial amyloid polyneuropathy. Tolcapone 40-49 transthyretin Homo sapiens 114-127 31119947-0 2019 Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Tolcapone 83-92 transthyretin Homo sapiens 0-13 31119947-0 2019 Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Tolcapone 83-92 transthyretin Homo sapiens 117-121 31119947-0 2019 Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Tolcapone 94-101 transthyretin Homo sapiens 0-13 31119947-0 2019 Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Tolcapone 94-101 transthyretin Homo sapiens 117-121 31119947-1 2019 Objective: To assess the transthyretin (TTR) stabilization activity of tolcapone (SOM0226) in patients with hereditary ATTR amyloidosis, asymptomatic carriers and healthy volunteers. Tolcapone 71-80 transthyretin Homo sapiens 25-38 31119947-1 2019 Objective: To assess the transthyretin (TTR) stabilization activity of tolcapone (SOM0226) in patients with hereditary ATTR amyloidosis, asymptomatic carriers and healthy volunteers. Tolcapone 71-80 transthyretin Homo sapiens 40-43 31119947-1 2019 Objective: To assess the transthyretin (TTR) stabilization activity of tolcapone (SOM0226) in patients with hereditary ATTR amyloidosis, asymptomatic carriers and healthy volunteers. Tolcapone 71-80 transthyretin Homo sapiens 119-123 31119947-10 2019 Conclusions: The ability of tolcapone for stabilizing TTR supports further development and repositioning of the drug for the treatment of ATTR amyloidosis. Tolcapone 28-37 transthyretin Homo sapiens 54-57 31119947-10 2019 Conclusions: The ability of tolcapone for stabilizing TTR supports further development and repositioning of the drug for the treatment of ATTR amyloidosis. Tolcapone 28-37 transthyretin Homo sapiens 138-142 28298647-5 2017 Tolcapone, which is bound with similar high affinity in both TTR binding sites without the usual negative cooperativity, is therefore of interest. Tolcapone 0-9 transthyretin Homo sapiens 61-64 28298647-6 2017 Here we show that TTR fibrillogenesis by the mechano-enzymatic pathway is indeed more potently inhibited by tolcapone than by tafamidis but neither, even in large molar excess, completely prevents amyloid fibril formation. Tolcapone 108-117 transthyretin Homo sapiens 18-21 26902880-0 2016 Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Tolcapone 14-23 transthyretin Homo sapiens 49-62 26902880-4 2016 Here we repurpose tolcapone, an FDA-approved molecule for Parkinson"s disease, as a potent TTR aggregation inhibitor. Tolcapone 18-27 transthyretin Homo sapiens 91-94 26902880-5 2016 Tolcapone binds specifically to TTR in human plasma, stabilizes the native tetramer in vivo in mice and humans and inhibits TTR cytotoxicity. Tolcapone 0-9 transthyretin Homo sapiens 32-35 26902880-5 2016 Tolcapone binds specifically to TTR in human plasma, stabilizes the native tetramer in vivo in mice and humans and inhibits TTR cytotoxicity. Tolcapone 0-9 transthyretin Homo sapiens 124-127 26902880-6 2016 Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses. Tolcapone 22-31 transthyretin Homo sapiens 51-54 26902880-6 2016 Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses. Tolcapone 22-31 transthyretin Homo sapiens 141-144 26902880-6 2016 Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses. Tolcapone 22-31 transthyretin Homo sapiens 141-144